Harvard Stem Cell Institute
The Harvard Stem Cell Institute (HSCI) was founded in 2004 to pursue the promise of stem cell science and regenerative medicine. We are a network working throughout the university, its eight affiliated hospitals, and the biomedical industry.
Our research focuses on understanding, and discovering cures for, diseases of aging, the blood, cancer, metabolism, skin and the nervous system. Our goal is to bring stem cell-based treatments to patients as quickly as possible.
The greater Boston area is home to the largest concentration of biomedical researchers in the world. This allows HSCI researchers to pull together and advance stem cell and regenerative medicine in a way no other single entity can.
Funded entirely by private philanthropy, we have helped change the paradigm for biomedical research and education by facilitating cross-institutional and cross-disciplinary collaboration, and by promoting advanced training in cutting-edge science.
We enable the world's top stem cell biologists to collaborate on a daily basis with scientist-physicians, chemists, bioengineers, and experts in business, law, and ethics to develop tomorrow's treatments today.
We support HSCI scientists in a number of ways, from providing seed grants for novel research to actively encouraging collaborative projects with industry. Our members also have access to Harvard core facilities to support their research, including:
- iPS Core Facility
- HSCI Therapeutic Screening Center
- Center for Human Cell Therapy (CHCT)/Trans Lab
- Flow cytometry cores at Boston Children's Hospital, Joslin Diabetes Center, Massachusetts General Hospital, and the Harvard University Department of Stem Cell and Regenerative Biology
- Production of clinical-grade cellular therapy products through the Connell O’Reilly Cell Manipulation Core Facility (DF/HCC) at DFC